Developmental Therapeutics and Pharmacology Unit

Sadhana Jackson, MD
Sadhana Jackson, MD

Dr. Sadhana Jackson attended Hampton University where she received her Bachelor of Science in Molecular Biology. She then obtained her MD from Eastern Virginia Medical School (EVMS) and subsequently completed a residency in Pediatrics at Orlando Health. After completing a fellowship in pediatric hematology/oncology at St. Jude Children’s Research Hospital, she finished her training at Johns Hopkins for a joint fellowship in pediatric neuro-oncology and clinical pharmacology.

Dr. Sadhana Jackson is a board-certified pediatrician and pediatric hematologist/oncologist with clinical expertise and research efforts related to the blood-brain barrier and malignant glioma. Her clinical practice focuses on drug delivery of systemic agents for pediatric malignant brain tumor patients. As a tenure-track Investigator in NINDS and NCI, Dr. Jackson ties her clinical practice to her research efforts focused on understanding the heterogeneous permeability of the blood-brain barrier amongst malignant gliomas. With her laboratory and clinical studies, her team aims to modulate the tumor microenvironment to enhance effective treatments to the CNS for malignant gliomas. She has extensive experience with use of intracerebral microdialysis to evaluate optimal drug entry to malignant tumors. Using exquisite tools to measure drug concentrations and agents to transiently disrupt the BBB, her research aims to maximize therapies for prolonged survival in aggressive pediatric brain tumors.


Lab Members:



Selected Publications:


Piotrowski AF, Jackson S (2022)
Identifying risk factors for recurrence/relapse in NF1 optic pathway gliomas: Moving forward by looking back.
Neuro Oncol, PubMed ID: 35325245

Lowden MR, Matthews M, Rivers RC, Hubbard LLN, Boone E, Muhammad T, Billingslea EN, Rohan JP, Simmons J, Jackson S (2022)
Grassroots efforts to end structural racism throughout the US National Institutes of Health.
Nat Med, 28:223-224. PubMed ID: 35132268


Argersinger DP, Rivas SR, Shah AH, Jackson S, Heiss JD (2021)
New Developments in the Pathogenesis, Therapeutic Targeting, and Treatment of H3K27M-Mutant Diffuse Midline Glioma.
Cancers (Basel), 13 PubMed ID: 34771443

Chukwueke UN, Vera E, Acquaye A, Hervey-Jumper SL, Odia Y, Klesse LJ, Dunbar E, Sharma A, Fonkem E, Thomas AA, Werbowetski-Ogilvie TE, Camelo-Piragua S, Gatson NTN, de la Fuente MI, Armstrong TS, Porter AB, Jackson S (2021)
SNO 2020 diversity survey: defining demographics, racial biases, career success metrics and a path forward for the field of neuro-oncology.
Neuro Oncol, 23:1845-1858. PubMed ID: 34302487

Martin AM, Jackson S (2021)
High-risk Medulloblastoma-Balancing the High Stakes of Molecular Profiling to Enhance Treatment Responsivity.
JAMA Oncol, 7:1322-1323. PubMed ID: 34292302

Collins FS, Adams AB, Aklin C, Archer TK, Bernard MA, Boone E, Burklow J, Evans MK, Jackson S, Johnson AC, Lorsch J, Lowden MR, Nápoles AM, Ordóñez AE, Rivers R, Rucker V, Schwetz T, Segre JA, Tabak LA, Hooper MW, Wolinetz C, (2021)
Affirming NIH's commitment to addressing structural racism in the biomedical research enterprise.
Cell, 184:3075-3079. PubMed ID: 34115967

Otani Y, Sur HP, Rachaiah G, Namagiri S, Chowdhury A, Lewis CT, Shimizu T, Gangaplara A, Wang X, Vézina A, Maric D, Jackson S, Yan Y, Zhengping Z, Ray-Chaudhury A, Kumar S, Ballester LY, Chittiboina P, Yoo JY, Heiss J, Kaur B, Banasavadi-Siddegowda YK (2021)
Inhibiting protein phosphatase 2A increases the antitumor effect of protein arginine methyltransferase 5 inhibition in models of glioblastoma.
Neuro Oncol, 23:1481-1493. PubMed ID: 33556161


Jackson S, Baker EH, Gross AM, Whitcomb P, Baldwin A, Derdak J, Tibery C, Desanto J, Carbonell A, Yohay K, O'Sullivan G, Chen AP, Widemann BC, Dombi E (2020)
The MEK inhibitor selumetinib reduces spinal neurofibroma burden in patients with NF1 and plexiform neurofibromas.
Neurooncol Adv, 2:vdaa095. PubMed ID: 32939452


Jackson S, Meeks C, Vézina A, Robey RW, Tanner K, Gottesman MM (2019)
Model systems for studying the blood-brain barrier: Applications and challenges.
Biomaterials, 214:119217. PubMed ID: 31146177


Jackson S, Weingart J, Nduom EK, Harfi TT, George RT, McAreavey D, Ye X, Anders NM, Peer C, Figg WD, Gilbert M, Rudek MA, Grossman SA (2018)
The effect of an adenosine A2A agonist on intra-tumoral concentrations of temozolomide in patients with recurrent glioblastoma.
Fluids Barriers CNS, 15:2. PubMed ID: 29332604


McCord M, Mukouyama YS, Gilbert MR, Jackson S (2017)
Targeting WNT Signaling for Multifaceted Glioblastoma Therapy.
Front Cell Neurosci, 11:318. PubMed ID: 29081735

Jackson S, George RT, Lodge MA, Piotrowski A, Wahl RL, Gujar SK, Grossman SA (2017)
The effect of regadenoson on the integrity of the human blood-brain barrier, a pilot study.
J Neurooncol, 132:513-519. PubMed ID: 28315063


Jackson S, Anders NM, Mangraviti A, Wanjiku TM, Sankey EW, Liu A, Brem H, Tyler B, Rudek MA, Grossman SA (2016)
The effect of regadenoson-induced transient disruption of the blood-brain barrier on temozolomide delivery to normal rat brain.
J Neurooncol, 126:433-9. PubMed ID: 26626489